Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 V777L||Advanced Solid Tumor||conflicting||Lapatinib||Preclinical||Actionable||In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).||22046346|
|ERBB2 V777L||Advanced Solid Tumor||conflicting||Lapatinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells expressing ERBB2 (HER2) V777L were resistant to Tykerb (lapatinib) in culture (PMID: 31588020).||31588020|
|PubMed Id||Reference Title||Details|
|(22046346)||Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.||Full reference...|
|(31588020)||Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.||Full reference...|